You have read all your free articles, to continue reading subscribe to read the rest of this content.
Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. This marks the first regulatory approval for a type I interferon (type I IFN) receptor antagonist and the onlyAlready a subscriber Login You…
AstraZeneca's Imfinzi (durvalumab) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for a new four-week, fixed-dose regimen for treatment in the approved indications of non-small cell lung cancer (NSCLC) and bladdAlready a subscriber Login You have read all your free…
The company has taken its first investment capital and a cunning business development partner. It is Nordiska Centrumhus that shares the Quretech Bio vision regarding new drugs against infectious diseases and antibiotic resistance by backing company growth in the region, reports Umeå Biotech IncubAlready a subscriber Login You have read…
Genmab and Seagen have announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) seeking accelerated approval for tisotumab vedotin. This BLA requests FDA approval of tisotumab vedotin for the treatment of patients with recAlready a subscriber Login You have read…
